Metabolic and bariatric surgery reduces cardiovascular risks in obesity.

A comparative analysis of metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy indicated that MBS significantly lowers the hazard of cardiovascular disease in patients with obesity. Specifically, MBS demonstrated a reduced risk for the primary composite outcome of cardiovascular disease (HR 0.54) and secondary outcomes including heart failure (HR 0.45), coronary artery disease (HR 0.54), and cerebrovascular disease (HR 0.64) over up to 10 years of follow-up.